{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T13:52:30Z","timestamp":1790949150325,"version":"4.1.0"},"reference-count":75,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Curr Urol Rep"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1007\/s11934-022-01125-6","type":"journal-article","created":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T11:05:52Z","timestamp":1668596752000},"page":"371-381","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Stereotactic Body Radiotherapy for Localized Kidney Cancer"],"prefix":"10.1007","volume":"23","author":[{"given":"Benjamin J.","family":"Rich","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Miguel Angel","family":"Noy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alan","family":"Dal Pra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,11,16]]},"reference":[{"issue":"1","key":"1125_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.3322\/caac.21708","volume":"72","author":"RL Siegel","year":"2022","unstructured":"Siegel RL, Miller KD, Fuchs HE, Jemal A. Cancer statistics, 2022. CA Cancer J Clin. 2022;72(1):7\u201333. https:\/\/doi.org\/10.3322\/caac.21708.","journal-title":"CA Cancer J Clin"},{"key":"1125_CR2","doi-asserted-by":"publisher","unstructured":"Padala SA, Barsouk A, Thandra KC, Saginala K, Mohammed A, Vakiti A, et al. Epidemiology of renal cell carcinoma. World J Oncol. 2020;11(3):79\u201387. https:\/\/doi.org\/10.14740\/wjon1279.","DOI":"10.14740\/wjon1279"},{"issue":"2","key":"1125_CR3","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1111\/j.1442-2042.1995.tb00428.x","volume":"2","author":"Y Homma","year":"1995","unstructured":"Homma Y, Kawabe K, Kitamura T, Nishimura Y, Shinohara M, Kondo Y, et al. Increased incidental detection and reduced mortality in renal cancer\u2013recent retrospective analysis at eight institutions. Int J Urol. 1995;2(2):77\u201380. https:\/\/doi.org\/10.1111\/j.1442-2042.1995.tb00428.x.","journal-title":"Int J Urol"},{"issue":"1","key":"1125_CR4","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1016\/j.eururo.2010.10.029","volume":"59","author":"M Sun","year":"2011","unstructured":"Sun M, Thuret R, Abdollah F, Lughezzani G, Schmitges J, Tian Z, et al. Age-adjusted incidence, mortality, and survival rates of stage-specific renal cell carcinoma in North America: a trend analysis. Eur Urol. 2011;59(1):135\u201341. https:\/\/doi.org\/10.1016\/j.eururo.2010.10.029.","journal-title":"Eur Urol"},{"issue":"1","key":"1125_CR5","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.eururo.2016.02.029","volume":"70","author":"H Moch","year":"2016","unstructured":"Moch H, Cubilla AL, Humphrey PA, Reuter VE, Ulbright TM. The 2016 WHO classification of tumours of the urinary system and male genital organs-part A: renal, penile, and testicular tumours. Eur Urol. 2016;70(1):93\u2013105. https:\/\/doi.org\/10.1016\/j.eururo.2016.02.029.","journal-title":"Eur Urol"},{"issue":"7","key":"1125_CR6","doi-asserted-by":"publisher","first-page":"e47","DOI":"10.1097\/PAS.0000000000001476","volume":"44","author":"SR Williamson","year":"2020","unstructured":"Williamson SR, Gill AJ, Argani P, Chen YB, Egevad L, Kristiansen G, et al. Report from the International Society of Urological Pathology (ISUP) consultation conference on molecular pathology of urogenital cancers: III: molecular pathology of kidney cancer. Am J Surg Pathol. 2020;44(7):e47\u201365. https:\/\/doi.org\/10.1097\/PAS.0000000000001476.","journal-title":"Am J Surg Pathol"},{"issue":"5","key":"1125_CR7","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1016\/j.eururo.2019.02.011","volume":"75","author":"B Ljungberg","year":"2019","unstructured":"Ljungberg B, Albiges L, Abu-Ghanem Y, Bensalah K, Dabestani S, Fernandez-Pello S, et al. European Association of Urology guidelines on renal cell carcinoma: the 2019 update. Eur Urol. 2019;75(5):799\u2013810. https:\/\/doi.org\/10.1016\/j.eururo.2019.02.011.","journal-title":"Eur Urol"},{"key":"1125_CR8","doi-asserted-by":"publisher","unstructured":"Mitchell TJ, Turajlic S, Rowan A, Nicol D, Farmery JHR, O'Brien T, et al. Timing the landmark events in the evolution of clear cell renal cell cancer: TRACERx renal. Cell. 2018;173(3):611\u201323 e17. https:\/\/doi.org\/10.1016\/j.cell.2018.02.020.","DOI":"10.1016\/j.cell.2018.02.020"},{"issue":"4","key":"1125_CR9","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41581-020-00359-2","volume":"17","author":"E Jonasch","year":"2021","unstructured":"Jonasch E, Walker CL, Rathmell WK. Clear cell renal cell carcinoma ontogeny and mechanisms of lethality. Nat Rev Nephrol. 2021;17(4):245\u201361. https:\/\/doi.org\/10.1038\/s41581-020-00359-2.","journal-title":"Nat Rev Nephrol"},{"issue":"18","key":"1125_CR10","doi-asserted-by":"publisher","first-page":"4407","DOI":"10.1158\/1078-0432.CCR-18-0323","volume":"24","author":"BI Rini","year":"2018","unstructured":"Rini BI, Escudier B, Martini JF, Magheli A, Svedman C, Lopatin M, et al. Validation of the 16-gene recurrence score in patients with locoregional, high-risk renal cell carcinoma from a phase III trial of adjuvant sunitinib. Clin Cancer Res. 2018;24(18):4407\u201315. https:\/\/doi.org\/10.1158\/1078-0432.CCR-18-0323.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"1125_CR11","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1016\/j.juro.2015.07.113","volume":"195","author":"RW Joseph","year":"2016","unstructured":"Joseph RW, Kapur P, Serie DJ, Parasramka M, Ho TH, Cheville JC, et al. Clear cell renal cell carcinoma subtypes identified by BAP1 and PBRM1 expression. J Urol. 2016;195(1):180\u20137. https:\/\/doi.org\/10.1016\/j.juro.2015.07.113.","journal-title":"J Urol"},{"issue":"9","key":"1125_CR12","doi-asserted-by":"publisher","first-page":"1341","DOI":"10.1007\/s00345-018-2286-7","volume":"36","author":"SH Rossi","year":"2018","unstructured":"Rossi SH, Klatte T, Usher-Smith J, Stewart GD. Epidemiology and screening for renal cancer. World J Urol. 2018;36(9):1341\u201353. https:\/\/doi.org\/10.1007\/s00345-018-2286-7.","journal-title":"World J Urol"},{"issue":"3","key":"1125_CR13","doi-asserted-by":"publisher","first-page":"231","DOI":"10.3109\/21681805.2013.864698","volume":"48","author":"A Thorstenson","year":"2014","unstructured":"Thorstenson A, Bergman M, Scherman-Plogell AH, Hosseinnia S, Ljungberg B, Adolfsson J, et al. Tumour characteristics and surgical treatment of renal cell carcinoma in Sweden 2005\u20132010: a population-based study from the national Swedish kidney cancer register. Scand J Urol. 2014;48(3):231\u20138. https:\/\/doi.org\/10.3109\/21681805.2013.864698.","journal-title":"Scand J Urol"},{"issue":"5","key":"1125_CR14","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2019-035938","volume":"10","author":"NS Vasudev","year":"2020","unstructured":"Vasudev NS, Wilson M, Stewart GD, Adeyoju A, Cartledge J, Kimuli M, et al. Challenges of early renal cancer detection: symptom patterns and incidental diagnosis rate in a multicentre prospective UK cohort of patients presenting with suspected renal cancer. BMJ Open. 2020;10(5): e035938. https:\/\/doi.org\/10.1136\/bmjopen-2019-035938.","journal-title":"BMJ Open"},{"issue":"2","key":"1125_CR15","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1097\/JU.0000000000001911","volume":"206","author":"SC Campbell","year":"2021","unstructured":"Campbell SC, Clark PE, Chang SS, Karam JA, Souter L, Uzzo RG. Renal mass and localized renal cancer: evaluation, management, and follow-up: AUA guideline: Part I. J Urol. 2021;206(2):199\u2013208. https:\/\/doi.org\/10.1097\/JU.0000000000001911.","journal-title":"J Urol"},{"issue":"5","key":"1125_CR16","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/annonc\/mdz056","volume":"30","author":"B Escudier","year":"2019","unstructured":"Escudier B, Porta C, Schmidinger M, Rioux-Leclercq N, Bex A, Khoo V, et al. Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-updagger. Ann Oncol. 2019;30(5):706\u201320. https:\/\/doi.org\/10.1093\/annonc\/mdz056.","journal-title":"Ann Oncol"},{"key":"1125_CR17","doi-asserted-by":"crossref","unstructured":"Motzer RJ, Jonasch, E, Agarwal N, Alva A, Baine M, Beckermann K, Carlo MI, Choueiri TK, Costello BA, Derweesh IH, Desai A, Ged Y, George S, Gore JL, Haas N, Hancock SL, Kapur P, Kyriakopoulos C, Lam ET, Lara PN, Lau C, Lewis B, Madoff DC, Manley B, Michaelson MD, Mortazavi A, Nandagopal L, Plimack ER, Ponsky L, Ramalingam S, Shuch B, Smith ZL, Sosman J, Dwyer MA, Gurski LA, Motter A (2022) Kidney Cancer, Version 3.2022, NCCN clinical practice guidelines in oncology. J Nat Comprehen Cancer Net 20(1):71\u201390.","DOI":"10.6004\/jnccn.2022.0001"},{"issue":"3 Pt 1","key":"1125_CR18","doi-asserted-by":"publisher","first-page":"746","DOI":"10.1097\/00005392-199709000-00013","volume":"158","author":"SJ DiBiase","year":"1997","unstructured":"DiBiase SJ, Valicenti RK, Schultz D, Xie Y, Gomella LG, Corn BW. Palliative irradiation for focally symptomatic metastatic renal cell carcinoma: support for dose escalation based on a biological model. J Urol. 1997;158(3 Pt 1):746\u20139. https:\/\/doi.org\/10.1097\/00005392-199709000-00013.","journal-title":"J Urol"},{"issue":"4","key":"1125_CR19","doi-asserted-by":"publisher","first-page":"e170","DOI":"10.1016\/S1470-2045(13)70569-2","volume":"15","author":"G De Meerleer","year":"2014","unstructured":"De Meerleer G, Khoo V, Escudier B, Joniau S, Bossi A, Ost P, et al. Radiotherapy for renal-cell carcinoma. Lancet Oncol. 2014;15(4):e170\u20137. https:\/\/doi.org\/10.1016\/S1470-2045(13)70569-2.","journal-title":"Lancet Oncol"},{"issue":"12","key":"1125_CR20","doi-asserted-by":"publisher","first-page":"4649","DOI":"10.1158\/0008-5472.CAN-07-6003","volume":"68","author":"KJ Champion","year":"2008","unstructured":"Champion KJ, Guinea M, Dammai V, Hsu T. Endothelial function of von Hippel-Lindau tumor suppressor gene: control of fibroblast growth factor receptor signaling. Cancer Res. 2008;68(12):4649\u201357. https:\/\/doi.org\/10.1158\/0008-5472.CAN-07-6003.","journal-title":"Cancer Res"},{"issue":"10 Suppl","key":"1125_CR21","doi-asserted-by":"publisher","first-page":"2282","DOI":"10.1002\/cncr.24238","volume":"115","author":"CN Qian","year":"2009","unstructured":"Qian CN, Huang D, Wondergem B, Teh BT. Complexity of tumor vasculature in clear cell renal cell carcinoma. Cancer. 2009;115(10 Suppl):2282\u20139. https:\/\/doi.org\/10.1002\/cncr.24238.","journal-title":"Cancer"},{"key":"1125_CR22","doi-asserted-by":"publisher","first-page":"17009","DOI":"10.1038\/nrdp.2017.9","volume":"3","author":"JJ Hsieh","year":"2017","unstructured":"Hsieh JJ, Purdue MP, Signoretti S, Swanton C, Albiges L, Schmidinger M, et al. Renal cell carcinoma. Nat Rev Dis Primers. 2017;3:17009. https:\/\/doi.org\/10.1038\/nrdp.2017.9.","journal-title":"Nat Rev Dis Primers"},{"key":"1125_CR23","doi-asserted-by":"publisher","first-page":"41","DOI":"10.3389\/fcell.2020.00041","volume":"8","author":"J Sia","year":"2020","unstructured":"Sia J, Szmyd R, Hau E, Gee HE. Molecular mechanisms of radiation-induced cancer cell death: a primer. Front Cell Dev Biol. 2020;8:41. https:\/\/doi.org\/10.3389\/fcell.2020.00041.","journal-title":"Front Cell Dev Biol"},{"issue":"4","key":"1125_CR24","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1007\/s10147-014-0717-z","volume":"19","author":"CW Song","year":"2014","unstructured":"Song CW, Kim MS, Cho LC, Dusenbery K, Sperduto PW. Radiobiological basis of SBRT and SRS. Int J Clin Oncol. 2014;19(4):570\u20138. https:\/\/doi.org\/10.1007\/s10147-014-0717-z.","journal-title":"Int J Clin Oncol"},{"issue":"1","key":"1125_CR25","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.ijrobp.2015.05.016","volume":"93","author":"CW Song","year":"2015","unstructured":"Song CW, Lee YJ, Griffin RJ, Park I, Koonce NA, Hui S, et al. Indirect tumor cell death after high-dose hypofractionated irradiation: implications for stereotactic body radiation therapy and stereotactic radiation surgery. Int J Radiat Oncol Biol Phys. 2015;93(1):166\u201372. https:\/\/doi.org\/10.1016\/j.ijrobp.2015.05.016.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"4","key":"1125_CR26","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1038\/s41419-020-2418-z","volume":"11","author":"J Ketteler","year":"2020","unstructured":"Ketteler J, Wittka A, Leonetti D, Roy VV, Estephan H, Maier P, et al. Caveolin-1 regulates the ASMase\/ceramide-mediated radiation response of endothelial cells in the context of tumor-stroma interactions. Cell Death Dis. 2020;11(4):228. https:\/\/doi.org\/10.1038\/s41419-020-2418-z.","journal-title":"Cell Death Dis"},{"issue":"5622","key":"1125_CR27","doi-asserted-by":"publisher","first-page":"1155","DOI":"10.1126\/science.1082504","volume":"300","author":"M Garcia-Barros","year":"2003","unstructured":"Garcia-Barros M, Paris F, Cordon-Cardo C, Lyden D, Rafii S, Haimovitz-Friedman A, et al. Tumor response to radiotherapy regulated by endothelial cell apoptosis. Science. 2003;300(5622):1155\u20139. https:\/\/doi.org\/10.1126\/science.1082504.","journal-title":"Science"},{"issue":"12","key":"1125_CR28","doi-asserted-by":"publisher","first-page":"8657","DOI":"10.1074\/jbc.275.12.8657","volume":"275","author":"T Lin","year":"2000","unstructured":"Lin T, Genestier L, Pinkoski MJ, Castro A, Nicholas S, Mogil R, et al. Role of acidic sphingomyelinase in Fas\/CD95-mediated cell death. J Biol Chem. 2000;275(12):8657\u201363. https:\/\/doi.org\/10.1074\/jbc.275.12.8657.","journal-title":"J Biol Chem"},{"issue":"38","key":"1125_CR29","doi-asserted-by":"publisher","first-page":"23721","DOI":"10.1073\/pnas.2001933117","volume":"117","author":"J Chow","year":"2020","unstructured":"\u2022 Chow J, Hoffend NC, Abrams SI, Schwaab T, Singh AK, Muhitch JB. Radiation induces dynamic changes to the T cell repertoire in renal cell carcinoma patients. Proc Natl Acad Sci U S A. 2020;117(38):23721\u20139. https:\/\/doi.org\/10.1073\/pnas.2001933117. This preclinical study demonstrates the ability of radiation therapy to activate the adaptive immune response in renal cell carcinoma suggesting a possible synergy between radiation and the immune system that could be exploited with immunotherapy.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"1125_CR30","doi-asserted-by":"publisher","first-page":"1744","DOI":"10.1016\/j.ijrobp.2011.02.040","volume":"82","author":"MJ Zelefsky","year":"2012","unstructured":"Zelefsky MJ, Greco C, Motzer R, Magsanoc JM, Pei X, Lovelock M, et al. Tumor control outcomes after hypofractionated and single-dose stereotactic image-guided intensity-modulated radiotherapy for extracranial metastases from renal cell carcinoma. Int J Radiat Oncol Biol Phys. 2012;82(5):1744\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2011.02.040.","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"1125_CR31","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1186\/1748-717X-6-34","volume":"6","author":"MA Stinauer","year":"2011","unstructured":"Stinauer MA, Kavanagh BD, Schefter TE, Gonzalez R, Flaig T, Lewis K, et al. Stereotactic body radiation therapy for melanoma and renal cell carcinoma: impact of single fraction equivalent dose on local control. Radiat Oncol. 2011;6:34. https:\/\/doi.org\/10.1186\/1748-717X-6-34.","journal-title":"Radiat Oncol"},{"issue":"9","key":"1125_CR32","doi-asserted-by":"publisher","first-page":"819","DOI":"10.2217\/fon-2017-0536","volume":"14","author":"W Haque","year":"2018","unstructured":"Haque W, Verma V, Lewis GD, Lo SS, Butler EB, Teh BS. Utilization of radiotherapy and stereotactic body radiation therapy for renal cell cancer in the USA. Future Oncol. 2018;14(9):819\u201327. https:\/\/doi.org\/10.2217\/fon-2017-0536.","journal-title":"Future Oncol"},{"issue":"5","key":"1125_CR33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.2217\/fon.16.2","volume":"12","author":"S Siva","year":"2016","unstructured":"Siva S, Ellis RJ, Ponsky L, Teh BS, Mahadevan A, Muacevic A, et al. Consensus statement from the International Radiosurgery Oncology Consortium for Kidney for primary renal cell carcinoma. Future Oncol. 2016;12(5):637\u201345. https:\/\/doi.org\/10.2217\/fon.16.2.","journal-title":"Future Oncol"},{"issue":"3","key":"1125_CR34","doi-asserted-by":"publisher","first-page":"540","DOI":"10.1016\/j.radonc.2016.01.027","volume":"118","author":"S Siva","year":"2016","unstructured":"Siva S, Jackson P, Kron T, Bressel M, Lau E, Hofman M, et al. Impact of stereotactic radiotherapy on kidney function in primary renal cell carcinoma: establishing a dose-response relationship. Radiother Oncol. 2016;118(3):540\u20136. https:\/\/doi.org\/10.1016\/j.radonc.2016.01.027.","journal-title":"Radiother Oncol"},{"issue":"5","key":"1125_CR35","doi-asserted-by":"publisher","first-page":"623","DOI":"10.1111\/bju.13811","volume":"120","author":"S Siva","year":"2017","unstructured":"Siva S, Pham D, Kron T, Bressel M, Lam J, Tan TH, et al. Stereotactic ablative body radiotherapy for inoperable primary kidney cancer: a prospective clinical trial. BJU Int. 2017;120(5):623\u201330. https:\/\/doi.org\/10.1111\/bju.13811.","journal-title":"BJU Int"},{"issue":"1","key":"1125_CR36","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.21623","volume":"14","author":"M Staehler","year":"2022","unstructured":"Staehler M, Schuler T, Spek A, Rodler S, Tamalunas A, Furweger C, et al. Propensity score-matched analysis of single fraction robotic radiosurgery versus open partial nephrectomy in renal cell carcinoma: oncological outcomes. Cureus. 2022;14(1): e21623. https:\/\/doi.org\/10.7759\/cureus.21623.","journal-title":"Cureus"},{"issue":"4","key":"1125_CR37","doi-asserted-by":"publisher","first-page":"941","DOI":"10.1016\/j.ijrobp.2020.06.014","volume":"108","author":"S Siva","year":"2020","unstructured":"\u2022 Siva S, Correa RJM, Warner A, Staehler M, Ellis RJ, Ponsky L, et al. Stereotactic ablative radiotherapy for >\/=T1b primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Int J Radiat Oncol Biol Phys. 2020;108(4):941\u20139. https:\/\/doi.org\/10.1016\/j.ijrobp.2020.06.014. This large, international study from the IROCK consortioum demonstrates the safety and efficacy of SBRT in patients with large, primary renal cell carcinomas.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"5","key":"1125_CR38","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cncr.31156","volume":"124","author":"S Siva","year":"2018","unstructured":"Siva S, Louie AV, Warner A, Muacevic A, Gandhidasan S, Ponsky L, et al. Pooled analysis of stereotactic ablative radiotherapy for primary renal cell carcinoma: a report from the International Radiosurgery Oncology Consortium for Kidney (IROCK). Cancer. 2018;124(5):934\u201342. https:\/\/doi.org\/10.1002\/cncr.31156.","journal-title":"Cancer"},{"issue":"5","key":"1125_CR39","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.eucr.2014.05.011","volume":"2","author":"M Hanzly","year":"2014","unstructured":"Hanzly M, Creighton T, Mix M, Zeeck K, Fung-Kee-Fung S, Singh AK, et al. Stereotactic body radiotherapy for the treatment of renal tumors. Urol Case Rep. 2014;2(5):147\u20139. https:\/\/doi.org\/10.1016\/j.eucr.2014.05.011.","journal-title":"Urol Case Rep"},{"issue":"5","key":"1125_CR40","doi-asserted-by":"publisher","first-page":"1061","DOI":"10.1016\/j.ijrobp.2014.07.043","volume":"90","author":"D Pham","year":"2014","unstructured":"Pham D, Thompson A, Kron T, Foroudi F, Kolsky MS, Devereux T, et al. Stereotactic ablative body radiation therapy for primary kidney cancer: a 3-dimensional conformal technique associated with low rates of early toxicity. Int J Radiat Oncol Biol Phys. 2014;90(5):1061\u20138. https:\/\/doi.org\/10.1016\/j.ijrobp.2014.07.043.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"2","key":"1125_CR41","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.adro.2019.10.001","volume":"5","author":"AV Peddada","year":"2020","unstructured":"Peddada AV, Anderson D, Blasi OC, McCollough K, Jennings SB, Monroe AT. Nephron-sparing robotic radiosurgical therapy for primary renal cell carcinoma: single-institution experience and review of the literature. Adv Radiat Oncol. 2020;5(2):204\u201311. https:\/\/doi.org\/10.1016\/j.adro.2019.10.001.","journal-title":"Adv Radiat Oncol"},{"key":"1125_CR42","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1016\/j.radonc.2020.10.031","volume":"155","author":"WR Grubb","year":"2021","unstructured":"\u2022 Grubb WR, Ponsky L, Lo SS, Kharouta M, Traughber B, Sandstrom K, et al. Final results of a dose escalation protocol of stereotactic body radiotherapy for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol. 2021;155:138\u201343. https:\/\/doi.org\/10.1016\/j.radonc.2020.10.031. This multi-insitutional phase I dose escalation trial demonstrated that SBRT up to a dose of 60 Gy in 3 fractions is well-tolerated for patients with localized renal cell carcinoma.","journal-title":"Radiother Oncol"},{"issue":"3","key":"1125_CR43","doi-asserted-by":"publisher","first-page":"544","DOI":"10.2214\/AJR.14.14099","volume":"206","author":"MR Sun","year":"2016","unstructured":"Sun MR, Brook A, Powell MF, Kaliannan K, Wagner AA, Kaplan ID, et al. Effect of stereotactic body radiotherapy on the growth kinetics and enhancement pattern of primary renal tumors. AJR Am J Roentgenol. 2016;206(3):544\u201353. https:\/\/doi.org\/10.2214\/AJR.14.14099.","journal-title":"AJR Am J Roentgenol"},{"issue":"5","key":"1125_CR44","doi-asserted-by":"publisher","first-page":"e851","DOI":"10.1016\/j.clgc.2017.03.012","volume":"15","author":"O Kaidar-Person","year":"2017","unstructured":"Kaidar-Person O, Price A, Schreiber E, Zagar TM, Chen RC. Stereotactic body radiotherapy for large primary renal cell carcinoma. Clin Genitourin Cancer. 2017;15(5):e851\u20134. https:\/\/doi.org\/10.1016\/j.clgc.2017.03.012.","journal-title":"Clin Genitourin Cancer"},{"issue":"1","key":"1125_CR45","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s12894-019-0531-z","volume":"19","author":"C Senger","year":"2019","unstructured":"Senger C, Conti A, Kluge A, Pasemann D, Kufeld M, Acker G, et al. Robotic stereotactic ablative radiotherapy for renal cell carcinoma in patients with impaired renal function. BMC Urol. 2019;19(1):96. https:\/\/doi.org\/10.1186\/s12894-019-0531-z.","journal-title":"BMC Urol"},{"issue":"3","key":"1125_CR46","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1080\/0284186X.2020.1866776","volume":"60","author":"V Grozman","year":"2021","unstructured":"Grozman V, Onjukka E, Wersall P, Lax I, Tsakonas G, Nyren S, et al. Extending hypofractionated stereotactic body radiotherapy to tumours larger than 70cc - effects and side effects. Acta Oncol. 2021;60(3):305\u201311. https:\/\/doi.org\/10.1080\/0284186X.2020.1866776.","journal-title":"Acta Oncol"},{"issue":"9","key":"1125_CR47","doi-asserted-by":"publisher","first-page":"e109","DOI":"10.1016\/j.clon.2016.04.002","volume":"28","author":"JH Chang","year":"2016","unstructured":"Chang JH, Cheung P, Erler D, Sonier M, Korol R, Chu W. Stereotactic ablative body radiotherapy for primary renal cell carcinoma in non-surgical candidates: initial clinical experience. Clin Oncol (R Coll Radiol). 2016;28(9):e109\u201314. https:\/\/doi.org\/10.1016\/j.clon.2016.04.002.","journal-title":"Clin Oncol (R Coll Radiol)"},{"key":"1125_CR48","doi-asserted-by":"publisher","unstructured":"Tetar SU, Bohoudi O, Senan S, Palacios MA, Oei SS, Wel AMV, et al. The role of daily adaptive stereotactic MR-guided radiotherapy for renal cell cancer. Cancers (Basel). 2020;12(10). https:\/\/doi.org\/10.3390\/cancers12102763.","DOI":"10.3390\/cancers12102763"},{"issue":"6","key":"1125_CR49","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1097\/COC.0000000000000329","volume":"41","author":"RJM Correa","year":"2018","unstructured":"Correa RJM, Rodrigues GB, Chen H, Warner A, Ahmad B, Louie AV. Stereotactic ablative radiotherapy (SABR) for large renal tumors: a retrospective case series evaluating clinical outcomes, toxicity, and technical considerations. Am J Clin Oncol. 2018;41(6):568\u201375. https:\/\/doi.org\/10.1097\/COC.0000000000000329.","journal-title":"Am J Clin Oncol"},{"issue":"5","key":"1125_CR50","doi-asserted-by":"publisher","first-page":"e313","DOI":"10.1016\/j.clgc.2021.04.010","volume":"19","author":"GC Blitzer","year":"2021","unstructured":"Blitzer GC, Wojcieszynski A, Abel EJ, Best S, Lee FT Jr, Hinshaw JL, et al. Combining stereotactic body radiotherapy and microwave ablation appears safe and feasible for renal cell carcinoma in an early series. Clin Genitourin Cancer. 2021;19(5):e313\u20138. https:\/\/doi.org\/10.1016\/j.clgc.2021.04.010.","journal-title":"Clin Genitourin Cancer"},{"key":"1125_CR51","doi-asserted-by":"publisher","unstructured":"Grelier L, Baboudjian M, Gondran-Tellier B, Couderc AL, McManus R, Deville JL, et al. Stereotactic body radiotherapy for frail patients with primary renal cell carcinoma: preliminary results after 4 years of experience. Cancers (Basel). 2021;13(13). https:\/\/doi.org\/10.3390\/cancers13133129.","DOI":"10.3390\/cancers13133129"},{"key":"1125_CR52","doi-asserted-by":"publisher","first-page":"153303381882232","DOI":"10.1177\/1533033818822329","volume":"18","author":"S Funayama","year":"2019","unstructured":"Funayama S, Onishi H, Kuriyama K, Komiyama T, Marino K, Araya M, et al. Renal cancer is not radioresistant: slowly but continuing shrinkage of the tumor after stereotactic body radiation therapy. Technol Cancer Res Treat. 2019;18:1533033818822329. https:\/\/doi.org\/10.1177\/1533033818822329.","journal-title":"Technol Cancer Res Treat"},{"issue":"3","key":"1125_CR53","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1093\/jrr\/rrab031","volume":"62","author":"T Yamamoto","year":"2021","unstructured":"Yamamoto T, Kawasaki Y, Umezawa R, Kadoya N, Matsushita H, Takeda K, et al. Stereotactic body radiotherapy for kidney cancer: a 10-year experience from a single institute. J Radiat Res. 2021;62(3):533\u20139. https:\/\/doi.org\/10.1093\/jrr\/rrab031.","journal-title":"J Radiat Res"},{"issue":"1","key":"1125_CR54","doi-asserted-by":"publisher","first-page":"183","DOI":"10.1016\/j.radonc.2015.08.030","volume":"117","author":"L Ponsky","year":"2015","unstructured":"Ponsky L, Lo SS, Zhang Y, Schluchter M, Liu Y, Patel R, et al. Phase I dose-escalation study of stereotactic body radiotherapy (SBRT) for poor surgical candidates with localized renal cell carcinoma. Radiother Oncol. 2015;117(1):183\u20137. https:\/\/doi.org\/10.1016\/j.radonc.2015.08.030.","journal-title":"Radiother Oncol"},{"issue":"4","key":"1125_CR55","doi-asserted-by":"publisher","first-page":"564","DOI":"10.1016\/j.jvir.2019.11.009","volume":"31","author":"A Uhlig","year":"2020","unstructured":"Uhlig A, Uhlig J, Trojan L, Kim HS. Stereotactic body radiotherapy for stage I renal cell carcinoma: national treatment trends and outcomes compared to partial nephrectomy and thermal ablation. J Vasc Interv Radiol. 2020;31(4):564\u201371. https:\/\/doi.org\/10.1016\/j.jvir.2019.11.009.","journal-title":"J Vasc Interv Radiol"},{"issue":"14","key":"1125_CR56","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1200\/JCO.18.01074","volume":"37","author":"PD Soni","year":"2019","unstructured":"Soni PD, Hartman HE, Dess RT, Abugharib A, Allen SG, Feng FY, et al. Comparison of population-based observational studies with randomized trials in oncology. J Clin Oncol. 2019;37(14):1209\u201316. https:\/\/doi.org\/10.1200\/JCO.18.01074.","journal-title":"J Clin Oncol"},{"key":"1125_CR57","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1186\/s13014-016-0651-5","volume":"11","author":"T Yamamoto","year":"2016","unstructured":"Yamamoto T, Kadoya N, Takeda K, Matsushita H, Umezawa R, Sato K, et al. Renal atrophy after stereotactic body radiotherapy for renal cell carcinoma. Radiat Oncol. 2016;11:72. https:\/\/doi.org\/10.1186\/s13014-016-0651-5.","journal-title":"Radiat Oncol"},{"issue":"1","key":"1125_CR58","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1118\/1.2818738","volume":"35","author":"K Otto","year":"2008","unstructured":"Otto K. Volumetric modulated arc therapy: IMRT in a single gantry arc. Med Phys. 2008;35(1):310\u20137. https:\/\/doi.org\/10.1118\/1.2818738.","journal-title":"Med Phys"},{"issue":"4","key":"1125_CR59","doi-asserted-by":"publisher","first-page":"323","DOI":"10.1016\/j.meddos.2016.09.001","volume":"41","author":"M Sonier","year":"2016","unstructured":"Sonier M, Chu W, Lalani N, Erler D, Cheung P, Korol R. Implementation of a volumetric modulated arc therapy treatment planning solution for kidney and adrenal stereotactic body radiation therapy. Med Dosim. 2016;41(4):323\u20138. https:\/\/doi.org\/10.1016\/j.meddos.2016.09.001.","journal-title":"Med Dosim"},{"key":"1125_CR60","doi-asserted-by":"publisher","DOI":"10.1002\/acm2.12308","author":"A Baydoun","year":"2018","unstructured":"Baydoun A, Vapiwala N, Ponsky LE, Awan M, Kassaee A, Sutton D, et al. Comparative analysis for renal stereotactic body radiotherapy using Cyberknife, VMAT and proton therapy based treatment planning. J Appl Clin Med Phys. 2018. https:\/\/doi.org\/10.1002\/acm2.12308.","journal-title":"J Appl Clin Med Phys"},{"issue":"10","key":"1125_CR61","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.1799","volume":"9","author":"MA Frick","year":"2017","unstructured":"Frick MA, Chhabra AM, Lin L, Simone CB 2nd. First ever use of proton stereotactic body radiation therapy delivered with curative intent to bilateral synchronous primary renal cell carcinomas. Cureus. 2017;9(10): e1799. https:\/\/doi.org\/10.7759\/cureus.1799.","journal-title":"Cureus"},{"issue":"3","key":"1125_CR62","doi-asserted-by":"publisher","first-page":"304","DOI":"10.1016\/j.meddos.2013.03.001","volume":"38","author":"D Pham","year":"2013","unstructured":"Pham D, Kron T, Foroudi F, Siva S. Effect of different breathing patterns in the same patient on stereotactic ablative body radiotherapy dosimetry for primary renal cell carcinoma: a case study. Med Dosim. 2013;38(3):304\u20138. https:\/\/doi.org\/10.1016\/j.meddos.2013.03.001.","journal-title":"Med Dosim"},{"key":"1125_CR63","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.ejmp.2021.07.020","volume":"89","author":"M Gaudreault","year":"2021","unstructured":"Gaudreault M, Siva S, Kron T, Hardcastle N. Reducing the impact on renal function of kidney SABR through management of respiratory motion. Phys Med. 2021;89:72\u20139. https:\/\/doi.org\/10.1016\/j.ejmp.2021.07.020.","journal-title":"Phys Med"},{"key":"1125_CR64","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1186\/1748-717X-8-248","volume":"8","author":"S Siva","year":"2013","unstructured":"Siva S, Pham D, Gill S, Bressel M, Dang K, Devereux T, et al. An analysis of respiratory induced kidney motion on four-dimensional computed tomography and its implications for stereotactic kidney radiotherapy. Radiat Oncol. 2013;8:248. https:\/\/doi.org\/10.1186\/1748-717X-8-248.","journal-title":"Radiat Oncol"},{"issue":"6","key":"1125_CR65","doi-asserted-by":"publisher","DOI":"10.1016\/j.adro.2021.100719","volume":"6","author":"N Chevli","year":"2021","unstructured":"Chevli N, Chiang SB, Farach AM, Haque W, Satkunasivam R, Bernicker EH, et al. DMSA-SPECT: a novel approach to nephron sparing SBRT for renal cell carcinoma. Adv Radiat Oncol. 2021;6(6): 100719. https:\/\/doi.org\/10.1016\/j.adro.2021.100719.","journal-title":"Adv Radiat Oncol"},{"issue":"1","key":"1125_CR66","doi-asserted-by":"publisher","first-page":"e55","DOI":"10.1016\/j.prro.2018.09.002","volume":"9","author":"FM Prins","year":"2019","unstructured":"Prins FM, Stemkens B, Kerkmeijer LGW, Barendrecht MM, de Boer HJ, Vonken EPA, et al. Intrafraction motion management of renal cell carcinoma with magnetic resonance imaging-guided stereotactic body radiation therapy. Pract Radiat Oncol. 2019;9(1):e55\u201361. https:\/\/doi.org\/10.1016\/j.prro.2018.09.002.","journal-title":"Pract Radiat Oncol"},{"issue":"18","key":"1125_CR67","doi-asserted-by":"publisher","first-page":"7407","DOI":"10.1088\/1361-6560\/aa83f7","volume":"62","author":"B Stemkens","year":"2017","unstructured":"Stemkens B, Glitzner M, Kontaxis C, de Senneville BD, Prins FM, Crijns SPM, et al. Effect of intra-fraction motion on the accumulated dose for free-breathing MR-guided stereotactic body radiation therapy of renal-cell carcinoma. Phys Med Biol. 2017;62(18):7407\u201324. https:\/\/doi.org\/10.1088\/1361-6560\/aa83f7.","journal-title":"Phys Med Biol"},{"issue":"3","key":"1125_CR68","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.meddos.2021.02.008","volume":"46","author":"T Kutuk","year":"2021","unstructured":"Kutuk T, McCulloch J, Mittauer KE, Romaguera T, Alvarez D, Gutierrez AN, et al. Daily online adaptive magnetic resonance image (MRI) guided stereotactic body radiation therapy for primary renal cell cancer. Med Dosim. 2021;46(3):289\u201394. https:\/\/doi.org\/10.1016\/j.meddos.2021.02.008.","journal-title":"Med Dosim"},{"issue":"5","key":"1125_CR69","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1097\/COC.0000000000000801","volume":"44","author":"J Aronowitz","year":"2021","unstructured":"Aronowitz J, Ding L, Yates J, Zong Y, Zheng L, Jiang Z, et al. Stereotactic body radiotherapy for palliation of hematuria arising from urothelial carcinoma of the kidney in unfavorable surgical candidates. Am J Clin Oncol. 2021;44(5):175\u201380. https:\/\/doi.org\/10.1097\/COC.0000000000000801.","journal-title":"Am J Clin Oncol"},{"key":"1125_CR70","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.eucr.2015.09.006","volume":"4","author":"A Nikolaev","year":"2016","unstructured":"Nikolaev A, Benda R. Palliative radiation therapy for symptomatic control of inoperable renal cell carcinoma. Urol Case Rep. 2016;4:51\u20132. https:\/\/doi.org\/10.1016\/j.eucr.2015.09.006.","journal-title":"Urol Case Rep"},{"issue":"2","key":"1125_CR71","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1016\/j.urolonc.2010.11.017","volume":"31","author":"JM Whitson","year":"2013","unstructured":"Whitson JM, Reese AC, Meng MV. Population based analysis of survival in patients with renal cell carcinoma and venous tumor thrombus. Urol Oncol. 2013;31(2):259\u201363. https:\/\/doi.org\/10.1016\/j.urolonc.2010.11.017.","journal-title":"Urol Oncol"},{"issue":"5","key":"1125_CR72","doi-asserted-by":"publisher","first-page":"657","DOI":"10.1080\/15384047.2015.1026506","volume":"16","author":"R Hannan","year":"2015","unstructured":"Hannan R, Margulis V, Chun SG, Cannon N, Kim DW, Abdulrahman RE, et al. Stereotactic radiation therapy of renal cancer inferior vena cava tumor thrombus. Cancer Biol Ther. 2015;16(5):657\u201361. https:\/\/doi.org\/10.1080\/15384047.2015.1026506.","journal-title":"Cancer Biol Ther"},{"issue":"4","key":"1125_CR73","doi-asserted-by":"publisher","first-page":"1135","DOI":"10.1016\/j.ijrobp.2021.01.054","volume":"110","author":"V Margulis","year":"2021","unstructured":"Margulis V, Freifeld Y, Pop LM, Manna S, Kapur P, Pedrosa I, et al. Neoadjuvant SABR for renal cell carcinoma inferior vena cava tumor thrombus-safety lead-in results of a phase 2 trial. Int J Radiat Oncol Biol Phys. 2021;110(4):1135\u201342. https:\/\/doi.org\/10.1016\/j.ijrobp.2021.01.054.","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"6","key":"1125_CR74","doi-asserted-by":"publisher","first-page":"958","DOI":"10.1016\/j.euf.2019.06.002","volume":"5","author":"RJM Correa","year":"2019","unstructured":"Correa RJM, Louie AV, Zaorsky NG, Lehrer EJ, Ellis R, Ponsky L, et al. The emerging role of stereotactic ablative radiotherapy for primary renal cell carcinoma: a systematic review and meta-analysis. Eur Urol Focus. 2019;5(6):958\u201369. https:\/\/doi.org\/10.1016\/j.euf.2019.06.002.","journal-title":"Eur Urol Focus"},{"key":"1125_CR75","doi-asserted-by":"publisher","unstructured":"Siva S, Chesson B, Bressel M, Pryor D, Higgs B, Reynolds HM, et al. TROG 15.03 phase II clinical trial of Focal Ablative STereotactic Radiosurgery for Cancers of the Kidney - FASTRACK II. BMC Cancer. 2018;18(1):1030. https:\/\/doi.org\/10.1186\/s12885-018-4916-2.","DOI":"10.1186\/s12885-018-4916-2"}],"container-title":["Current Urology Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-022-01125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s11934-022-01125-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s11934-022-01125-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,10]],"date-time":"2023-01-10T16:09:55Z","timestamp":1673366995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s11934-022-01125-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,11,16]]},"references-count":75,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["1125"],"URL":"https:\/\/doi.org\/10.1007\/s11934-022-01125-6","relation":{},"ISSN":["1527-2737","1534-6285"],"issn-type":[{"value":"1527-2737","type":"print"},{"value":"1534-6285","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,11,16]]},"assertion":[{"value":"3 September 2022","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 November 2022","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"This article does not contain any studies with human or animal subjects performed by any of the authors.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Human and Animal Rights\u00a0and Informed Consent"}}]}}